A Dark Vector Cognition product

Item 2. PROPERTIES

3K characters. Original on sec.gov · Markdown

Item 2. PROPERTIES

Our corporate headquarters are located at 530 Herman O. West Drive, Exton, Pennsylvania. This building also houses our North American sales and marketing, administrative support and customer service functions, as well as laboratories.

The following table summarizes production facilities by segment and geographic region. All facilities shown are owned except where otherwise noted.

Packaging Systems
Manufacturing:
North American OperationsEuropean OperationsAsia Pacific Operations
United StatesDenmarkChina
Clearwater, FLHorsensQingpu
Jersey Shore, PAEnglandIndia
Kearney, NESt. AustellSri City
Kinston, NCFranceSingapore
Lititz, PALe NouvionJurong
St. Petersburg, FL (1)Germany
Eschweiler (1)
South American OperationsStolberg
BrazilSerbia
Sao PauloKovin
Mold-and-Die Tool Shop:Contract Analytical Laboratory:
North American OperationsEuropean OperationsNorth American Operations
United StatesEnglandUnited States
Upper Darby, PABodmin (2)Exton, PA
Delivery Systems
Manufacturing:
North American OperationsEuropean Operations
United StatesFrance
Frankford, IN (2)Le Vaudreuil (2)
Grand Rapids, MIIreland
Phoenix, AZ (2)Dublin (2)
Scottsdale, AZ (2)(3)
Tempe, AZ (2)
Williamsport, PA
Puerto Rico
Cayey
(1)This manufacturing facility is also used for research and development activities.
(2)This facility is leased in whole or in part.
(3)This manufacturing facility is also used for mold and die production.

Our Delivery Systems segment leases facilities located in Israel, New Jersey and Texas for research and development, as well as other activities. Sales offices in various locations are leased under short-term arrangements.

In October 2014, we announced plans to expand our global manufacturing operations to include a new facility in Waterford, Ireland, which will produce packaging components for insulin injector cartridges and other high-value packaging components. Construction began in July 2015.

Previous: Item 1A. RISK FACTORS · Next: Item 3. LEGAL PROCEEDINGS